Neo Pharma Private Limited - Due diligence report

A 360° intelligence report on Neo Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and dist…

1950-03-09 Mumbai, Maharashtra Active Unlisted Active Compliant
Share
NP Neo Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Neo Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
78/100
Trust Score
Low Risk

Neo Pharma Private Limited is assessed as Low Risk with a Trust Score of 78/100. Neo Pharma Private Limited is an active private limited indian non-government company incorporated in 1950, operating in the Real Estate and Construction sector. Reported revenue has declined across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.

Report generated on 16 Jul 2026 from the latest processed filings. Neo Pharma Private Limited snapshot & full profile →

Financial Health › Good
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
78/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
72/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
65/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
40/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreModerate
50/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Consolidated · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 40/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Profitable - internal accruals available.

Charges position: 4 open (4,947.31 cr) · 13 satisfied (1,458.00 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Hdfc Bank Limited1 48.0 cr
Others15 48.0 cr
Axis Bank Limited1 48.0 cr
Compliance Score: 72/100 Moderate
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 4 court forum(s).
  • Delayed payments to MSME suppliers disclosed (10 disclosure(s)).
  • 1 active GST registration(s).
Legal cases on record (4)
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
JAYANT CHAGANLAL OSWAL 01234567 Director 01/04/2018 6 yrs Approved
Nikunj Pravinchandra Pandya 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
1
Capital events
3 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Longulf Trading (india) Private Limited Associate Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 50 · Distress 75
Growth signals & trust indicators
Net margin improved to 1.42.
EPFO headcount growing - hiring signal.
Operating for 76+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
4 open charge(s) registered - assets are encumbered.
MSME payment delays disclosed - latest outstanding 13.24 Lakh.
4 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence75/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment56/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 4 open charge(s) of 4,947.31 cr already registered.
  • Compliance record supports lending.
Investor view62/100
Mixed indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
15 Oct 2025
Charge satisfied
Others
30 Sep 2025
Last AGM held
Annual general meeting
18 Apr 2025
Director appointed
Nikunj Pravinchandra Pandya (Additional Director)
31 Mar 2025
Latest balance sheet
Filed with ROC
11 Nov 2024
Charge satisfied
Others
30 Sep 2024
Charge created
Others - 55.00 cr
27 Jun 2023
Charge satisfied
Others
30 Nov 2022
Charge satisfied
Others
22 Apr 2022
Charge created
Others - 100.00 cr
11 Apr 2022
Charge satisfied
Others
31 Dec 2021
Director ceased
BAJRANG LAL BARARIA
30 Apr 2021
Charge created
Hdfc Bank Limited - 4,572.31 cr
31 Mar 2021
Securities allotted
1750 Debentures - 175.00 cr raised
Charge created
Others - 175.00 cr
30 Mar 2021
Charge satisfied
Others
10

Key Observations

Auto-generated from the data above
Revenue declined 2.1x over the last 4 financial year(s).
Net profit margin moved from 24% to 0.86.
Debt-to-equity stands at 61% - leverage worth monitoring.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Shivshambho Constructions Private Limited U45200WB2020PTC238897 Piarapur, West Bengal, India
Platinum Holdings Private Limited U45202TN2006PTC059598 Chennai, Tamil Nadu, India
Thakur Infra Constructions Private Limited U70109PB2020PTC052041 Jalandhar, Punjab, India
Asv Constructions Private Limited U45201TN2003PTC051260 Chennai-10., Tamil Nadu, India
E-City Projects Construction Private Limited U45200MH2005PTC153860 Mumbai, Maharashtra, India
Bptp Parklands Pride Limited U70109HR2006PLC106281 Faridabad, Haryana, India
Il&Fs U70102MH2011PLC222987 Mumbai, Maharashtra, India
Spade Projects Private Limited U70109UR2018PTC008488 Dehradun, Uttarakhand, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Neo Pharma Private Limited before audits and certifications: compliance score 72/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Neo Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 40/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Mixed indicators. Growth score 50/100, margin trends, ownership structure and peer set for Neo Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 78/100, distress signals and MSME payment-delay disclosures - know whether Neo Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (4 case(s) on record), regulatory flags, charge documents trail and director networks for Neo Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Neo Pharma Private Limited an active company?

Neo Pharma Private Limited has MCA status “Active” with a compliance score of 72/100 (Moderate).

Is Neo Pharma Private Limited financially healthy?

Neo Pharma Private Limited has a Financial Health Score of 65/100 (Moderate) based on its filed financial statements.

Should I do business with Neo Pharma Private Limited?

Its overall Trust Score is 78/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Neo Pharma Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Neo Pharma Private Limited have loans or charges against its assets?

4 open charge(s) are registered against its assets, and 13 earlier charge(s) stand satisfied.

Is Neo Pharma Private Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 72/100 (Moderate).

Is it risky to lend to Neo Pharma Private Limited?

Its Credit Risk Score is 40/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.